{
    "title": "CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8",
    "pmcid": "PMC3548984",
    "summary": "The article assesses the impact of CYP2D6 genotypes on the efficacy of tamoxifen in treating postmenopausal women with estrogen receptor-positive breast cancer within the ABCSG Trial 8. It discusses how variations in CYP2D6 metabolism significantly influenced disease recurrence risks during tamoxifen therapy (5 years), with poor metabolizers (PM) showing higher odds of adverse events compared to extensive metabolizers (EM). Notably, once patients switched to anastrozole, the detrimental effects associated with poor CYP2D6 metabolism were no longer observed, indicating that anastrozole treatment may mitigate these risks. The study highlights that CYP2D6 genetic profiling may be necessary to optimize tamoxifen therapy outcomes without factoring in future transitions to more effective treatments like anastrozole.",
    "study_parameters": [
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.04",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.45,
            "Confidence Interval Start": 1.05,
            "Confidence Interval Stop": 5.73,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.07",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.67,
            "Confidence Interval Start": 0.95,
            "Confidence Interval Stop": 2.93,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.09",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.4,
            "Confidence Interval Start": 0.86,
            "Confidence Interval Stop": 6.66,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 319,
            "Study Controls": 557,
            "Characteristics": "CYP2D6 genotype and treatment with tamoxifen or anastrozole in post-menopausal women with ER positive breast cancer",
            "Characteristics Type": "drug",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "> 0.05",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 0.28,
            "Confidence Interval Start": 0.03,
            "Confidence Interval Stop": 2.3,
            "Biogeographical Groups": "European",
            "Variant Annotation ID_norm": null
        }
    ],
    "var_drug_ann": [
        {
            "Variant/Haplotypes": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen, anastrozole",
            "Phenotype Category": "metabolism/PK",
            "Significance": "yes",
            "Notes": "In Arm A during the first 5 years of therapy, women with 2 poor alleles had a higher likelihood of an event than women with two extensive alleles. In years 3-5, PM/PM tended towards a higher likelihood of a disease event relative to EM/EM among women on Arm A but not among women on Arm B.",
            "Sentence": "Genotype PM/PM is associated with increased odds of a disease event during tamoxifen treatment in postmenopausal women with estrogen receptor positive breast cancer.",
            "Alleles": "PM/PM",
            "Metabolizer types": "poor metabolizer",
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "Specialty Population": "Geriatric",
            "Population types": "in postmenopausal women",
            "Population Phenotypes or diseases": "Disease:breast cancer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": "response to",
            "Multiple drugs And/or": "",
            "Multiple phenotypes or diseases And/or": "",
            "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In years 3-5 when patients remained on tamoxifen (Arm A), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86-6.66, p=0.09) among women on Arm A but not among women on Arm B.",
                "The negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
            ]
        }
    ],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "CYP2D6 *4",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen",
            "PMID": 23213055,
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "Women with CYP2D6 *4 alleles showed higher risk of disease events during tamoxifen therapy in Arm A.",
            "Sentence": "CYP2D6 *4 is associated with increased likelihood of disease events when treated with tamoxifen in women with ER positive breast cancer.",
            "Alleles": "PM/PM, EM/EM",
            "Specialty Population": "post-menopausal women",
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "disease events",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in women with",
            "Population Phenotypes or diseases": "ER positive breast cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Comparison Metabolizer types": "extensive metabolizer",
            "PMID_norm": "23213055",
            "Variant Annotation ID_norm": "1",
            "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95-2.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "In ABCSG8, the negative effects of reduced CYP2D6 metabolism were observed only during the period of tamoxifen administration, and not after switching to anastrozole."
            ]
        }
    ],
    "var_fa_ann": [
        {
            "Variant/Haplotypes": "CYP2D6 *3, *4, *6, *10, *41",
            "Gene": "CYP2D6",
            "Drug(s)": "tamoxifen, anastrozole",
            "Phenotype Category": "efficacy",
            "Significance": "yes",
            "Notes": "Women with 2 poor alleles (PM/PM) had OR=2.45 (95% CI: 1.05-5.73, p=0.04) during Arm A. In Arm A, PM/IM or PM/EM had OR=1.67 (95% CI: 0.95-2.93, p=0.07). No significant association in Arm B during the same period.",
            "Standardized Sentence": "CYP2D6 *4/*4 is associated with increased likelihood of disease event when treated with tamoxifen compared to CYP2D6 EM/EM.",
            "Alleles": "*3/*3, *4/*4, *6/*6, *10/*10, *41/*41",
            "Metabolizer Types": "PM, IM",
            "Comparison Allele(s) or Genotype(s)": "EM/EM",
            "Is/Is Not associated": "Associated with",
            "Direction of Effect": "increased",
            "Functional terms": "likelihood of disease event",
            "Gene/gene product": "CYP2D6",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Assay type": "Genotyping using TaqmanÂ® Allelic Discrimination Assay",
            "Cell type": "Tumor tissue samples from paraffin-embedded blocks",
            "Multiple drugs And/or": "or",
            "Citations": [
                "In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05-5.73, p=0.04) had a higher likelihood of an event than women with two extensive alleles (EM/EM).",
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "For women on Arm A who remained event-free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91-3.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM."
            ]
        }
    ]
}